- Home
- NBN vs DAWN Comparison
NBN vs DAWN Comparison
Compare NBN & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBN
- DAWN
- Stock Information
- Founded
- NBN 1872
- DAWN 2018
- Country
- NBN United States
- DAWN United States
- Employees
- NBN N/A
- DAWN N/A
- Industry
- NBN Major Banks
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- NBN Finance
- DAWN Health Care
- Exchange
- NBN Nasdaq
- DAWN Nasdaq
- Market Cap
- NBN 766.7M
- DAWN 658.9M
- IPO Year
- NBN N/A
- DAWN 2021
- Fundamental
- Price
- NBN $93.36
- DAWN $6.76
- Analyst Decision
- NBN Buy
- DAWN Strong Buy
- Analyst Count
- NBN 2
- DAWN 6
- Target Price
- NBN $97.50
- DAWN $30.17
- AVG Volume (30 Days)
- NBN 112.5K
- DAWN 1.4M
- Earning Date
- NBN 07-28-2025
- DAWN 08-05-2025
- Dividend Yield
- NBN 0.04%
- DAWN N/A
- EPS Growth
- NBN 32.98
- DAWN N/A
- EPS
- NBN 10.08
- DAWN N/A
- Revenue
- NBN $204,086,000.00
- DAWN $161,922,000.00
- Revenue This Year
- NBN $36.62
- DAWN $16.42
- Revenue Next Year
- NBN $11.46
- DAWN $47.52
- P/E Ratio
- NBN $9.25
- DAWN N/A
- Revenue Growth
- NBN 33.67
- DAWN N/A
- 52 Week Low
- NBN $61.74
- DAWN $6.08
- 52 Week High
- NBN $110.35
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- NBN 47.31
- DAWN 46.52
- Support Level
- NBN $92.33
- DAWN $6.32
- Resistance Level
- NBN $105.50
- DAWN $7.18
- Average True Range (ATR)
- NBN 3.30
- DAWN 0.29
- MACD
- NBN -0.65
- DAWN -0.01
- Stochastic Oscillator
- NBN 7.59
- DAWN 30.56
About NBN Northeast Bank
Northeast Bank provides banking and financial services to individual and corporate customers in the US. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived primarily from interest and dividends from the bank.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.